CytoDyn Inc. (OTCMKTS:CYDY) Stock Continues to Fall: Down 8% in a Week
CytoDyn Inc. (OTCMKTS:CYDY) is down 8% in week. The company has submitted a Breakthrough Therapy Designation application to the FDA for leronlomab as a possible mTNBC treatment. Trading Data On Monday, CYDY stock slid 0.87% at $1.14 with more than 3.04 million shares, compared to its average volume of 2.35 million shares. The stock has moved within a range of $1.1250 – 1.1900 after opening the trade at $1.16. Major…